INTRODUCTION
============

Nicotine dependence is a chronic, relapsing addiction ([@bib32]), that afflicts \>20% of the population worldwide ([@bib14]). Nicotine exerts its effect primarily at heterogeneous acetylcholine receptors (nAChRs) in the brain. This activity stimulates dopaminergic and other pathways and this increase in dopamine contributes to the rewarding effects of nicotine ([@bib10]). The principal subtypes of these pentameric receptors include *α*4 and *β*2 subunits, sometimes complimented by additional subunits of a different type (eg, *α*5) ([@bib37]; [@bib43]). Nicotine shows high affinity for *α*4*β*2-containing nicotinic receptors, with *K*~i~ values in the low nanomolar range ([@bib19]).

The persistence of smoking can be attributed to multiple diverse causes. Chief among these are genetic risk factors contributing to smoking behavior ([@bib34]; [@bib35]; [@bib49]; [@bib50]). Genome-wide association studies (GWAS) have identified a primary genetic locus on chromosome 15q25 that increases the likelihood of nicotine dependence by 30--40% in individuals who carry common risk alleles ([@bib1]; [@bib23]; [@bib51]), as well as increasing the risk for several smoking-related diseases ([@bib4]; [@bib30]; [@bib42]; [@bib51]). This locus includes three nicotinic receptor subunit genes (*CHRNA5*, *CHRNB4*, and *CHRNA3*), and a gene expressed in the lungs (*IREB2*), any (or several) of which may contain variants that contribute to nicotine dependence risk ([@bib11]). Indeed, evidence points to the presence of multiple independent polymorphisms associated with nicotine dependence ([@bib46], [@bib48]). GWAS meta-analyses have identified four additional loci associated with nicotine dependence ([@bib50]; [@bib52]). Two of these loci map close to additional nicotinic receptor subunits (*CHRNA6* and *CHRNB3*) and to enzymes important for the metabolism of nicotine (*CYP2A6* and *CYP2B6*).

An additional factor in the persistence of smoking behaviors is the difficulty in quitting. Although many methods have been developed that improve quit rates, none is effective in all smokers ([@bib32]). Among these methods are several pharmacological agents, including nicotine replacement therapy (NRT), bupropion, and varenicline. Bupropion is a dopamine/norepinephrine reuptake inhibitor that also acts as a nicotinic receptor antagonist ([@bib53]); varenicline is a partial agonist of the *α*4*β*2 nAChR subtype ([@bib7]). The determinants of successful smoking cessation, like nicotine dependence itself, are likely to be diverse. The genetic components of successful smoking cessation are less well understood than nicotine dependence itself, although, like nicotine dependence, a significant proportion (∼50%) of the likelihood of quitting is genetic in origin ([@bib5]; [@bib33]; [@bib54]), suggesting that specific genetic risk factors could be identified. Indeed, the chromosome 15q25 locus described above has been associated with successful quitting in pregnant women ([@bib16]). However, many of the genetic loci affecting quitting are likely to be distinct from genetic determinants of nicotine dependence ([@bib35]; [@bib50]; [@bib52]).

In order to better understand the genetic determinants of smoking cessation, recent pharmacogenetic studies have investigated genes that may impact nicotine or bupropion activity and metabolism, and also components of the dopaminergic system related to addiction ([@bib8]; [@bib28]; [@bib31]; [@bib43]). Although replications are needed, variants identified in *CYP2B6* and *CHRNB2* may influence cessation rates for bupropion ([@bib8]; [@bib31]), and variants in the choline acetyltransferase (*CHAT*) gene may influence the success of NRT ([@bib43]). In addition, several pharmacogenomics studies have investigated the effect of nicotine metabolism rates directly, through analysis of nicotine metabolites ([@bib3]) with reproducible associations with smoking cessation ([@bib44]).

Here, we describe the first pharmacogenetic analysis of smoking cessation in a large population of smokers derived from placebo-controlled clinical trials testing the efficacy of varenicline and bupropion. In addition to drug metabolizing and nicotinic receptor genes, we investigated the primary varenicline transporter (*SLC22A2*), additional genes in the chromosome 15q25 locus (*IREB2*, *LOC123688*, and *PSMA4*), and two serotonin receptors (*HTR3A* and *HTR3B*) whose expression in the gut may contribute to nausea while on varenicline treatment ([@bib17]). We also examined whether variation in these candidate genes is associated with time to relapse to smoking or to nausea while on treatment.

PATIENTS AND METHODS
====================

Study Population
----------------

Subjects included in this study had participated in one of three randomized, double-blind, placebo-controlled smoking cessation clinical trials comparing varenicline, a nAChR partial agonist, with bupropion, a norepinephrine and dopamine reuptake inhibitor, and placebo ([Box 1](#box1){ref-type="boxed-text"}). The three trials have been described in detail previously ([@bib18]; [@bib26]; [@bib39]). In brief, all of the studies included a 12-week treatment period and 40-week non-treatment follow-up. Participants were healthy men and women; all had smoked an average of at least 10 cigarettes per day (CPD) during the past year, with no period of abstinence longer than 3 months, and were motivated to quit. For these clinical trials, patients were excluded if they had a history of alcohol or other drug abuse or dependence in the previous 12 months. Clinical trial endpoints included carbon monoxide-confirmed continuous abstinence from weeks 9 to 12 and weeks 9 to 52 ([@bib18]; [@bib26]; [@bib39]), and time to smoking relapse. Relapse to smoking after abstinence from weeks 9 to 12 was indicated either by patient-reported cigarette (as little as a single puff) or other nicotine use, or by an expiratory carbon monoxide measurement exceeding 10 p.p.m.

An optional blood sample was collected from clinical trial subjects for pharmacogenetic analysis to investigate potential associations between genetic variants and varenicline response and general characteristics of smoking cessation. Sample collection was not required for participation in the original clinical trials; however, \>50% of clinical trial subjects across all treatment arms volunteered to participate in the pharmacogenetic analysis.

Genotyping
----------

Candidate genes of interest included the genes identified on Chr15q25 (including the *CHRNA5*, *CHRNA3*, and *CHRNB4* gene cluster), the remaining nAChR subunit genes, genes encoding the varenicline transporter (*SLC22A2)* and serotonergic targets hypothesized to be involved in varenicline-induced nausea (*HTR3A, HTR3B)*, as well as cytochrome P450 (CYP) genes involved in nicotine and bupropion metabolism ([Box 2](#box2){ref-type="boxed-text"}). Varenicline is highly selective for the *α*4*β*2 nicotinic receptor (Ki=0.17 nM) ([@bib41]), but also shows moderate affinity (Ki=350 nM) for the 5-HT~3~ receptor and other common nicotinic receptors.

Primary genotyping was performed on the Illumina GoldenGate platform, with 975 candidate gene single-nucleotide polymorphisms (SNPs) and 216 ancestry informative marker SNPs. In addition, 89 complementary SNPs were genotyped using ABI Taqman and SNPlex methods. Genotyping call rates for all samples were ⩾94% (mean=99.8% median=99.8%). Genotyping call rates for all SNPs were ⩾97% (mean=99.8%, median=99.9%). SNPs were tested for Hardy--Weinberg equilibrium. In total, 12 SNPs were significantly out of HWE (*p*\<0.0001). None of these were associated with any phenotypes tested here. Multidimensional scaling analysis of the ancestry informative markers identified four subjects that did not cluster with the subjects of European ancestry. These subjects were excluded from the analysis.

Statistical Analysis
--------------------

Genetic associations for continuous abstinence rates and nausea incidence were assessed using logistic regression, assuming an additive genetic model. A survival model was used to assess the relapse data; specifically, a proportional hazards model was fitted to determine whether the time to relapse was affected by genotype. The proportional hazards assumption was checked using plots of the log-log survival (relapse) curves. The relapse analysis also assumed an additive genetic model. Our analysis was limited to SNPs whose minor allele frequency was \>5% in our overall genotyped population, reducing the total number of candidate gene SNPs analyzed to 785. For each analysis, a treatment × genotype interaction term was initially included in the model. For markers with at least marginally significant interaction with treatment (*p*\<0.20), the analysis was performed for each treatment group separately, as well as for all subjects together and adjusted for treatment. When the interaction was not significant, the data were analyzed as a single pooled sample, adjusted for treatment. To correct for multiple testing in which many markers were in strong linkage disequilibrium (LD), we selected individual SNPs representing bins of highly linked SNPs (*r*^2^\>0.8), with a single SNP for each bin included in a false discovery rate, multiple test correction approach (bins were derived from the Caucasian population described here). This reduced the total estimated number of independent tests from 785 to 254. All of the *p*-values reported here fell below a *q*-value of 0.2, using this approach.

RESULTS
=======

Study Population
----------------

Across the three trials, 2699 patients were randomized to treatment (including 826 to varenicline 1.0 mg twice per day titrated dose, 671 to bupropion, and 814 to placebo). DNA was extracted from blood samples of 1476 consenting individuals (524 varenicline; 440 bupropion; 512 placebo), and primary genetic analysis was performed on 1175 smokers of European ancestry. The genotyped subset was comparable to the overall clinical data set for baseline characteristics and outcomes, including age, gender, race, weight, smoking history, Fagerström Test for Nicotine Dependence, therapeutic smoking cessation response (continuous abstinence from weeks 9 to 12), and adverse event profile (including nausea incidence with varenicline).

Baseline Characteristics
------------------------

The demographic and smoking history characteristics of genotyped participants from the three clinical trials are shown in [Table 1](#tbl1){ref-type="table"}. Patients in the analysis had a mean age of approximately 43 years, and nearly 50% of the population was female. They smoked on average 22 CPD (SD 9.4), and an average score of 5.3 on the Fagerström Test for Nicotine Dependence (SD 2.1) indicated a moderate level of addiction. There were no significant differences in demographic variables or baseline characteristics across the three treatment groups.

Analysis of baseline smoking behavior among all genotyped subjects, as measured by the number of CPD, revealed a genetic association with the primary nicotine dependence locus on chromosome 15q25, indicating that the population studied here is consistent with previous populations evaluated for nicotine dependence ([@bib51]). The most significant SNP detected in this region was rs4275821 (*p*\<0.003), although we also detected nominal associations with other SNPs, including rs16969968 (*p*\<0.03). The CPD association with the 15q25 region was detected in this population despite the absence of a full range of smoking phenotypes (individuals smoking \<10 CPD were excluded from the clinical trials) ([@bib18]; [@bib26]; [@bib39]). We also detected an association between the 15q25 locus and scores from the Fagerström Test for Nicotine Dependence (*p*\<0.004, rs12443170).

Continuous Abstinence
---------------------

SNPs associated with continuous abstinence during weeks 9--12 of the treatment period are shown in [Table 2](#tbl2){ref-type="table"}. Among the subjects randomized to varenicline treatment, two polymorphisms in *CHRNB2* (rs3811450 and rs4262952) were associated with the largest increased odds of continuous smoking abstinence from weeks 9 to 12 (OR=2.52 (CI: 1.32--4.78); OR=2.44 (CI: 1.28--4.63)). Additionally, there were significant associations of SNPs within the chromosome 15q25 locus, as well as the *CHRNA4* and *CHRNA7* gene loci. The SNP most significantly associated with continuous abstinence from weeks 9 to 12 in the varenicline-treated smokers, rs7164594, is within the 15q25 locus and is in strong LD with rs2036534 (*r*^2^=0.98), a SNP previously determined to be significantly associated with lung cancer ([@bib1]) ([Figure 1a](#fig1){ref-type="fig"}).

Among the bupropion-treated subjects and in all three treatment groups combined, continuous abstinence at weeks 9--12 was strongly associated with several SNPs in *CYP2B6* as well as two SNPs in *CHRND*, which encodes the nAChR delta subunit. Interestingly, one of the *CYP2B6* SNPs (rs8109525; [Figure 1b](#fig1){ref-type="fig"}) is contained within a LD bin that includes rs7260329, a SNP recently identified to be significantly associated with the number of cigarettes smoked per day ([@bib52]). rs7260329 itself is nominally associated with continuous abstinence in the bupropion and combined populations, although to a lesser degree (*p*\<0.008, *p*\<0.02, respectively; *q* values \>0.2). No SNP tested was significantly associated with abstinence on placebo treatment.

During longer-term follow-up, through 52 weeks, no polymorphism was significantly associated with continuous abstinence in the varenicline or placebo treatment groups. However, in the bupropion group, as well as in the three treatment groups combined, continuous abstinence was again associated with several SNPs within *CYP2B6* ([Table 3](#tbl3){ref-type="table"}), including rs8109525 (*p*=0.0028, [Figure 1b](#fig1){ref-type="fig"}). Several of the polymorphisms tested in *CYP2B6* were in LD with this SNP (including rs7260329, described above); however, none of these linked SNPs correspond to functionally described CYP2B6 alleles ([@bib2]). In the combined treatment group, variants in *CYP2A6* were also significantly associated with continued abstinence.

Relapse to Smoking, Following Successful Quitting, All Treatments
-----------------------------------------------------------------

For all treatment groups combined, time to smoking relapse following initial abstinence from weeks 9--12 was associated with SNPs in *HTR3B* (rs11606194, rs3758987) and *HTR3A* (rs11607240) ([Table 4](#tbl4){ref-type="table"}). [Figure 2](#fig2){ref-type="fig"} shows the time to relapse associated with the two most predictive SNPs, rs11606194 and rs3758987.

Nausea
------

In these clinical trials, the adverse event most commonly reported in patients receiving varenicline (1 mg twice per day) was nausea ([@bib18]; [@bib26]; [@bib39]). Nausea was reported by 30% of individuals in the varenicline group (ranging from 28% to 35% across the three clinical trials) *vs* 10% in the bupropion group, and 9% in the placebo group. The incidence of nausea in the varenicline treatment group, and in all three treatment groups combined, was associated primarily with SNPs in the chromosome 15q25 locus ([Table 5](#tbl5){ref-type="table"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Among varenicline-treated patients, nausea was most significantly associated with rs555018 in the *CHRNA5* gene (OR=1.62; 95% CI: 1.19--2.20) and rs1190449 in the *CHRNG* gene (OR=1.57; 95% CI: 1.18--2.08), while in the three treatment groups combined, the most significant association was with rs6495309 in the *CHRNB4* gene (OR=0.50; 95% CI: 0.36--0.70; *p*=4.04E--05).

DISCUSSION
==========

This study represents the first genetic association study of varenicline for smoking cessation. The pharmacogenetic analysis, focusing largely on gene loci encoding nicotinic cholinergic receptor subunits and drug metabolizing enzymes, offers preliminary evidence that variants in *CHRNA4*, *CHRNB2*, and *CHRNA7* as well as in the 15q25 LD chromosomal region, including the nAChR genes *CHRNA3*, *CHRNA5*, and *CHRNB4*, influence the outcome (success or failure) of smoking cessation attempts with varenicline. In contrast, genetic analysis of response to bupropion suggests that the success of smoking cessation with this drug is determined in part by variation in *CYP2B6*, the gene encoding the primary enzyme responsible for the metabolism of bupropion ([@bib13]), rather than by genetic variation in nicotinic cholinergic receptor pathways. In addition to smoking cessation pharmacogenetics, we also evaluated pharmacogenetic associations with the presence of nausea while attempting to quit smoking, as well as relapse to smoking following a successful period of continuous abstinence. As with response to varenicline, genetic variation in the nicotinic cholinergic receptor genes appears to contribute to the risk of experiencing nausea during smoking cessation, and interestingly, relapse to smoking was significantly associated with polymorphisms in the serotonergic receptor genes, *HTR3A* and *HTR3B*.

Varenicline
-----------

Response to varenicline treatment is associated here with polymorphisms in multiple loci encoding nicotinic receptor subunits. Chief among these are the *CHRNA4* and *CHRNB2* loci, encoding the *α*4 and *β*2 nicotinic receptor subunits. Receptors comprised of these subunits are the specific targets of varenicline\'s activity, thus it is perhaps not surprising that these loci would be associated with varenicline response. In addition to these loci, there is also an association to varenicline response with polymorphisms in the chr15q25 locus. This, too, is consistent with varenicline activity, particularly given recent evidence demonstrating the importance of *α*5 subunits in predominantly *α*4*β*2 nicotinic receptors and the emergence of risk alleles in this locus as a primary factor in nicotine dependence ([@bib15]; [@bib29]; [@bib55]). An association between the 15q25 locus and response to varenicline also supports an argument that response to varenicline is related to nicotine dependence itself. Due to the high degree of LD among loci in this region, it is difficult to discriminate causative loci. The positive markers for varenicline response are in LD (\>0.6) with nicotine dependence markers (as well as markers for nausea; see below), thus these associations may be reflecting common functional alleles. In fact, the alleles that are associated with increased odds of quitting with varenicline are in LD with alleles associated with a decreased risk of nicotine dependence. This may be true of bupropion and placebo responders as well, although there are not sufficient subjects in these groups to detect such an effect. The relevance of the association with the *CHRNA7* locus is less clear, although varenicline does bind to homopentameric *α*7 nicotinic receptors ([@bib7]), however with reduced affinity in comparison with *α*4*β*2 receptors ([@bib1]; [@bib23]; [@bib51]).

Previous pharmacogenetic studies of smoking cessation, focusing on bupropion treatment, also identified polymorphisms in *CHRNB2* associated with treatment response. In each of these studies, there is evidence to suggest that response to treatment in the placebo group may also be associated with *CHRNB2*, albeit to a lesser degree ([@bib8]; [@bib20]; [@bib40]). In our study, we detect a similar, nominal association in our placebo group with a *CHRNB2* SNP (rs2072659, *p*=0.003, *q*=0.38). Thus, the genetic association of *CHRNB2* with response to varenicline might be explained in part by an increased likelihood to quit, regardless of treatment.

Bupropion
---------

In our study, we observed an association between *CYP2B6* polymorphisms and response to bupropion treatment. *CYP2B6* is the primary metabolizing enzyme for bupropion (as well as a secondary enzyme for nicotine metabolism) thus the effectiveness of bupropion treatment in smoking cessation may be determined by the rate of its metabolism, as indicated by the *CYP2B6* genotype. This is consistent with previous studies, in which *CYP2B6* polymorphisms have been shown to affect the pharmacokinetics of bupropion ([@bib27]) and the likelihood of achieving abstinence with bupropion in smoking cessation trials ([@bib31]). However, the polymorphisms associated with response to bupropion in our study differed from those identified in previous studies (which were not successfully genotyped in our study), thus this does not represent a true replication. A better understanding of these associations may come from the identification and characterization of additional functional alleles affecting *CYP2B6* activity or expression.

Overall Quit Success at 1 Year
------------------------------

The nicotinic receptor polymorphisms associated with response to varenicline measured from weeks 9 to 12 were not associated with continuous abstinence through the non-treatment follow-up period (including all weeks 9--52). During this period, no markers were significantly associated with continuous abstinence in the varenicline-treated smokers alone. In contrast, among the smokers treated with bupropion, *CYP2B6* polymorphisms were associated with continuous abstinence from weeks 9 to 52, as well as weeks 9 to 12. In fact, this association with *CYP2B6* polymorphisms extended to all smokers, regardless of treatment during the first 12 weeks. This may be due to a broader effect of *CYP2B6* on nicotine dependence, independent of its role in bupropion metabolism. This interpretation is consistent with a prior study identifying an association of a functional *CYP2B6* SNP with placebo response in a bupropion clinical trial ([@bib31]). Alternatively, this genetic signal, although more proximate to *CYP2B6*, may have a more direct effect on the adjacent *CYP2A6* locus, which is itself associated with continuous abstinence from weeks 9 to 52. In addition to (or perhaps because of) its role in nicotine metabolism, the *CYP2A6* locus has also recently been found to be genetically associated with nicotine dependence ([@bib50]; [@bib52]), and phenotypic markers of nicotine metabolism rate have reproducible associations with prospective smoking cessation ([@bib44]). Continuous abstinence from weeks 9 to 52 also showed weaker associations with *HTR3B* and *CHRNA10* in the entire cohort. The association with *HTR3B* may be explained relative to its association with relapse to smoking (described below). The potential role of *CHRN10A* in smoking cessation is less clear, although it has been shown recently to be associated with nicotine dependence in an African-American population ([@bib46], [@bib48]).

Relapse
-------

We analyzed time to relapse to smoking in the subset of subjects who successfully quit smoking while on treatment during weeks 9--12, but relapsed during weeks 13--52. Unexpectedly, the strongest associations with this phenotype were with polymorphisms in genes encoding the serotonin receptors *HTR3A* and *HTR3B*. These genes were originally included in our study to test whether they might be related to nausea associated with varenicline treatment, although they are expressed widely in the brain as well as the gut ([@bib38]). Previous investigations using an *HTR3* antagonist, ondansetron, provide some insights into why these loci may be important for relapse to smoking. This medicine, originally developed to prevent nausea ([@bib9]), has been shown to lower cravings for alcohol and to ease the withdrawal symptoms of opioid addictions ([@bib6]; [@bib25]). These results and our observations raise the intriguing possibility that this serotonin receptor family may be mediating its effects on relapse by impacting nicotine withdrawal symptoms, suggesting a potential role for HTR3 inhibition in reducing such withdrawal symptoms, regardless of the initial treatment method.

Nausea
------

In this study, the primary locus associated with nausea while attempting to quit smoking was the chr15q25 locus. This locus, which includes genes encoding the *β*4, *α*5, and *α*3 nicotinic receptor subunits (*CHRNB4*, *CHRNA5*, and *CHRNA3*), is the predominant locus associated with nicotine dependence ([@bib1]; [@bib23]; [@bib51]). Carriers of risk alleles at this locus are 30--40% more likely to become nicotine dependent. As with the response to varenicline, the significant LD in this region suggests that these associations are likely to overlap with those for nicotine dependence, and thus nausea experienced while quitting may be directly related to nicotine dependence. Smokers who are more dependent smoke more cigarettes per day and have a higher daily intake of nicotine. The link between the chr15q25 locus genes and nausea may be explained by tolerance, such that those with a greater daily intake of nicotine are more tolerant and therefore experience less nausea in response to a nicotinic partial agonist such as varenicline. Alternatively, incidence of nausea may be elevated in subjects with greater risk for nicotine dependence because their nicotine intake is greater before quitting, therefore exacerbating the symptoms of withdrawal on quitting. SNPs associated with nausea are also linked to SNPs associated with the expression of CHRNA5, suggesting another mechanistic link between nicotine dependence and nausea on quitting. For subjects treated with varenicline, *CHRNG*, which encodes the nAChRγ subunit, is also associated with nausea. The importance of this locus for nausea in the varenicline-treated subjects is not clear, although recent studies have identified associations with this region, which also includes the *CHRND* gene, and nicotine dependence ([@bib47]), suggesting that the association with nausea may also be driven by nicotine dependence.

Strengths and Limitations of This Study
---------------------------------------

The recent successes of genome-wide genetic association studies have highlighted the need for large study populations in order to detect the small effect sizes often associated with common genetic polymorphisms. However, most pharmacogenomic studies conducted to date have involved relatively small sample populations ([@bib22]). Thus, the strengths of this analysis include: (a) its large sample population---the largest such study to date of bupropion for smoking cessation, the first (and therefore also largest) pharmacogenetic analysis of varenicline, and the first head-to-head analysis of these treatments; and (b) the availability of robust phenotypic data from three rigorously controlled clinical trials, providing a database of patient data, adverse events, and, importantly, carbon monoxide-confirmed smoking cessation outcomes. Limitations of this analysis include: (a) a lack of generalizability of the study findings to non-treatment-seeking smokers---although the highly motivated (to quit smoking) population recruited to these trials is the subset of the broader smoking population to which pharmacogenetic tailoring approaches would be provided, efforts to encourage non-motivated smokers to quit may have different pharmacogenetic characteristics; and (b) a lack of ethnic diversity among the sample population---the candidate gene analysis was limited to individuals of European ancestry in order to avoid the effects of population stratification, and the relatively small number of subjects of non-European descent in our population prevented meaningful analysis of this latter group. For this reason, the study findings may not apply to populations of non-European descent. These results will also require replication in independent populations for validation. Ideally, larger populations will also permit a genome-wide analysis of smoking cessation pharmacogenetics, which could identify additional novel loci affecting these phenotypes.

Future Perspectives
-------------------

The goal of pharmacogenetic studies of smoking cessation therapy is to help increase the likelihood of an individual quitting smoking, and reduce the likelihood of adverse effects of smoking cessation therapy by individualizing treatment strategies according to genetic profile. Although pharmacogenetic tests for some conditions have had successful application in clinical practice ([@bib36]; [@bib45]), this has not been without challenges ([@bib21]; [@bib24]). Even leaving aside issues of cost-effectiveness and concerns around tests that could result in effective therapies being withheld ([@bib12]), several important issues need to be considered before pharmacogenetic testing for selection of smoking cessation treatment becomes standard clinical practice. Multiple genes and environmental factors probably combine to influence the response to smoking cessation therapies, yet most pharmacogenetic studies currently focus on a limited set of alleles and/or single genes and have limited power to account for gene--gene and gene--environment interactions. The development of effective individualized treatments for smoking cessation will likely require that future pharmacogenetic studies evaluate these multifactorial interactions. However, despite such challenges, access to larger populations and more detailed information regarding the molecular genetics of nicotine dependence and smoking cessation should lead to better optimization of cessation approaches, and to a reduction in overall smoking prevalence.

CONCLUSIONS
===========

These data provide both novel and supporting evidence for genetic loci contributing to smoking cessation and therapeutic response. Importantly, different genetic signals are associated with varenicline *vs* bupropion treatment response, suggesting that future research may lead to clinically useful markers to guide treatment decisions, resulting in improved smoking cessation rates overall, and a reduction in smoking prevalence.
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###### Characteristics of Genotyped Patients from the Clinical Trials

                              **Varenicline**   **Bupropion**   **Placebo**
  --------------------------- ----------------- --------------- -------------
  Age (SD)                    43.8 (11.1)       42.7 (12.0)     42.7 (11.9)
  Gender, % male              52                56              57
  Race, % Caucasian           82                82              79
  Weight, kg (SD)             79.7 (16.2)       79.0 (15.9)     79.3 (15.6)
  Smoking history, CPD (SD)   22.5 (9.9)        21.9 (8.7)      22.3 (9.7)
  FTND total score (SD)       5.34 (2.2)        5.27 (2.1)      5.28 (2.0)

Abbreviations: CPD, cigarettes per day; FTND, Fagerström Test for Nicotine Dependence.

###### Pharmacogenomics of Continuous Abstinence at Weeks 9--12

  **SNP**     **MAF**   **Gene**       **Region**  **Varenicline *p*-value**   **OR**   **95% CI**   ***q*-value**
  ----------- --------- ------------- ------------ --------------------------- -------- ------------ ---------------
  rs7164594   0.21      *LOC123688*      15q25     0.0019                      1.76     1.23--2.52   0.181
  rs3787138   0.13      *CHRNA4*         20q13     0.0030                      1.89     1.24--2.88   0.181
  rs6494212   0.30      *CHRNA7*         15q13     0.0038                      1.58     1.16--2.15   0.181
  rs3811450   0.07      *CHRNB2*          1q21     0.0048                      2.52     1.32--4.78   0.181
  rs2236196   0.27      *CHRNA4*         20q13     0.0063                      1.54     1.13--2.09   0.181
  rs4292956   0.07      *CHRNB2*          1q21     0.0067                      2.44     1.28--4.63   0.181
  rs518425    0.28      *CHRNA5*         15q25     0.0071                      1.62     1.14--2.31   0.181
  rs6062899   0.18      *CHRNA4*         20q13     0.0071                      1.63     1.14--2.33   0.181
  rs2938674   0.21      *IREB2*          15q25     0.0095                      1.60     1.12--2.27   0.196
                                                   **Bupropion *p*-value**                            
  rs8109525   0.34      *CYP2B6*         19q13     0.0008                      1.78     1.27--2.50   0.120
  rs3762528   0.07      *CHRND*           2q37     0.0012                      2.98     1.54--5.77   0.120
  rs1808682   0.25      *CYP2B6*         19q13     0.0030                      1.70     1.20--2.41   0.154
  rs6725786   0.10      *CHRND*           2q37     0.0036                      2.23     1.30--3.84   0.154
  rs1042389   0.20      *CYP2B6*         19q13     0.0038                      1.90     1.23--2.92   0.154
  rs2113103   0.16      *CYP2B6*         19q13     0.0049                      1.82     1.20--2.76   0.167
                                                   **Overall *p*-value**                              
  rs8109525   0.34      *CYP2B6*         19q13     0.0011                      1.37     1.13--1.66   0.111
  rs1808682   0.25      *CYP2B6*         19q13     0.0013                      1.40     1.14--1.72   0.111
  rs2014141   0.40      *CYP2B6*         19q13     0.0020                      0.75     0.62--0.90   0.115
  rs2113103   0.16      *CYP2B6*         19q13     0.0030                      1.43     1.13--1.82   0.129
  rs6010918   0.05      *CHRNA4*         20q13     0.0048                      1.75     1.19--2.59   0.167

Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.

###### Pharmacogenomics of Continuous Abstinence at Weeks 9--52

  **SNP**      **MAF**   **Gene**     **Region**  **Bupropion *p*-value**   **OR**   **95% CI**   ***q*-value**
  ------------ --------- ----------- ------------ ------------------------- -------- ------------ ---------------
  rs1808682    0.251     *CYP2B6*       19q13     0.00008                   2.27     1.51--3.40   0.019
  rs1042389    0.201     *CYP2B6*       19q13     0.0003                    2.49     1.52--4.09   0.036
  rs2113103    0.156     *CYP2B6*       19q13     0.0010                    2.16     1.36--3.43   0.087
  rs8100458    0.339     *CYP2B6*       19q13     0.0028                    1.82     1.23--2.70   0.180
                                                  **Overall *p*-value**                            
  rs1808682    0.251     *CYP2B6*       19q13     0.0001                    1.58     1.25--1.99   0.019
  rs11606194   0.076     *HTR3B*        11q23     0.0023                    0.47     0.29--0.76   0.197
  rs892216     0.348     *CYP2B6*       19q13     0.0042                    1.37     1.11--1.70   0.197
  rs7123164    0.115     *CHRNA10*      11p15     0.0050                    1.55     1.14--2.11   0.197
  rs7255616    0.067     *CYP2A6*       19q13     0.0057                    1.69     1.16--2.45   0.197

Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.

rs8109525, shown in [Figure 1](#fig1){ref-type="fig"}, is in strong LD with both rs8100458 and rs892216 (*r*^2^\>0.95).

No SNPs were associated with continuous abstinence in patients receiving varenicline.

###### Loci Associated With Relapse During Weeks 12--52, Among Those who had Successfully Quit at Weeks 9--12, All Groups Combined (*n*=420)

  **SNP**      **MAF**   **Gene**    **Region**  ***p*-value**   **HR**   **95% CI**   ***q*-value**
  ------------ --------- ---------- ------------ --------------- -------- ------------ ---------------
  rs11606194   0.076     *HTR3B*       11q23     1.53E--05       1.97     1.45--2.68   0.003
  rs3758987    0.271     *HTR3B*       11q23     0.0006          1.46     1.18--1.81   0.049
  rs11607240   0.074     *HTR3A*       11q23     0.0015          1.65     1.21--2.25   0.084

Abbreviations: CI, confidence interval; HR, hazard ratio; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.

###### Nausea Pharmacogenomics, Overall

  **SNP**      **MAF**   **Gene**     **Region**  ***p*-value**   **OR**    **95% CI**  ***q*-value**
  ------------ --------- ----------- ------------ --------------- -------- ------------ ---------------
  rs6495309    0.205     *CHRNB4*       15q25     4.04E--05       0.50      0.36--0.70  0.007
  rs4887072    0.216     *CHRNB4*       15q25     0.0002          0.55      0.40--0.75  0.015
  rs1878399    0.424     *CHRNA3*       15q25     0.0012          1.48      1.17--1.87  0.066
  rs1190449    0.447     *CHRNG*         2q37     0.0021          1.42      1.13--1.77  0.092
  rs6741278    0.369     *CHRNG*         2q37     0.0033          0.69      0.54--0.88  0.099
  rs578776     0.273     *CHRNA3*       15q25     0.0039          0.67      0.51--0.88  0.099
  rs595374     0.215     *SLC22A2*       6q25     0.0040          0.64      0.48--0.87  0.099
  rs4243083    0.416     *PSMA4*        15q25     0.0049          1.40      1.11--1.77  0.105
  rs684513     0.197     *CHRNA5*       15q25     0.0076          0.65      0.48--0.89  0.138
  rs12899425   0.274     *IREB2*        15q25     0.0087          1.39      1.09--1.77  0.138
  rs2869546    0.370     *CHRNA3*       15q25     0.0088          1.37      1.08--1.73  0.138
  rs11899983   0.437     *CHRNG*         2q37     0.0113          1.34      1.07--1.68  0.157
  rs17406522   0.072     *IREB2*        15q25     0.0125          1.67      1.12--2.50  0.157
  rs12443170   0.126     *CHRNA3*       15q25     0.0128          0.62      0.42--0.90  0.157
  rs12441998   0.199     *CHRNB4*       15q25     0.0151          0.68      0.50--0.93  0.173

Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.

###### Box 1 Varenicline Clinical Studies Included in the Pharmacogenetics Analysis
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###### Box 2 Candidate Gene List
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